DexCom, Inc. (NASDAQ:DXCM) – Equities research analysts at Oppenheimer raised their Q4 2021 earnings estimates for shares of DexCom in a report released on Wednesday, January 12th. Oppenheimer analyst S. Lichtman now forecasts that the medical device company will post earnings of $0.92 per share for the quarter, up from their previous forecast of $0.91. Oppenheimer has a “Outperform” rating and a $625.00 price objective on the stock. Oppenheimer also issued estimates for DexCom’s FY2022 earnings at $3.60 EPS and FY2023 earnings at $4.92 EPS.
A number of other research analysts also recently issued reports on the company. raised their price target on DexCom from $500.00 to $625.00 and gave the stock a “buy” rating in a research note on Friday, October 29th. Robert W. Baird lifted their target price on DexCom from $520.00 to $625.00 and gave the company an “outperform” rating in a research note on Friday, October 29th. Guggenheim upgraded DexCom from a “neutral” rating to a “buy” rating and set a $580.00 target price on the stock in a research note on Friday, January 7th. Morgan Stanley lowered their target price on DexCom from $576.00 to $570.00 and set an “equal weight” rating on the stock in a research note on Friday, January 7th. Finally, SVB Leerink lifted their target price on DexCom from $500.00 to $715.00 and gave the company an “outperform” rating in a research note on Friday, October 29th. Two research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, DexCom currently has an average rating of “Buy” and an average price target of $582.50.
DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, October 28th. The medical device company reported $0.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.27. The firm had revenue of $650.20 million for the quarter, compared to the consensus estimate of $617.07 million. DexCom had a return on equity of 14.65% and a net margin of 22.82%. The firm’s quarterly revenue was up 29.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.94 EPS.
In other news, CEO Kevin R. Sayer sold 3,000 shares of the business’s stock in a transaction on Monday, November 15th. The stock was sold at an average price of $647.84, for a total value of $1,943,520.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Steven Robert Pacelli sold 250 shares of the business’s stock in a transaction on Friday, October 22nd. The stock was sold at an average price of $570.00, for a total value of $142,500.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 14,420 shares of company stock valued at $8,597,547. 0.52% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in DXCM. MUFG Americas Holdings Corp acquired a new position in shares of DexCom in the third quarter worth $36,000. Jacobi Capital Management LLC raised its holdings in shares of DexCom by 31.8% in the second quarter. Jacobi Capital Management LLC now owns 87 shares of the medical device company’s stock worth $37,000 after acquiring an additional 21 shares during the last quarter. Farmers & Merchants Investments Inc. raised its holdings in shares of DexCom by 45.1% in the third quarter. Farmers & Merchants Investments Inc. now owns 74 shares of the medical device company’s stock worth $40,000 after acquiring an additional 23 shares during the last quarter. Itau Unibanco Holding S.A. acquired a new position in shares of DexCom in the second quarter worth $43,000. Finally, Logan Capital Management Inc. raised its holdings in shares of DexCom by 77.3% in the third quarter. Logan Capital Management Inc. now owns 78 shares of the medical device company’s stock worth $43,000 after acquiring an additional 34 shares during the last quarter. 94.26% of the stock is owned by institutional investors.
DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.
Featured Article: Commodities
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.